In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Kabi AG

Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com

Latest From Fresenius Kabi AG

US Appeal Against 2021 Cabazitaxel Patent Falls Flat

An attempt by Accord, Actavis, Apotex, Kabi and Mylan to overturn a US patent protecting Sanofi’s Jevtana cabazitaxel cancer drug until 2021 has failed. And claims in a patent running until 2031 could yet return to haunt the generics firms.

Intellectual Property Cancer

Kabi Is Ready To Get More Aggressive On US Market Share

With supply shortages easing and a period of channel destocking largely over, Fresenius Kabi’s US injectables business is preparing to fight hard to maintain its market position, group CEO Stephan Sturm says.

Business Strategies Pricing Strategies

Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.

Biosimilars Reimbursement

EU Biosimilar Filings, Opinions And Approvals

A list of new EU biosimilar product filings, CHMP opinions and marketing authorizations issued by the European Commission. The updated list includes the filing of the first biosimilar version of insulin aspart and the approval of the EU’s sixth biosimilar pegfilgrastim product.

European Performance Tracker Approvals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register